The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma and one of the most challenging blood cancers to combat due to frequent relapse after treatment. Here, we developed the first-in-class BTK/PI3K/BRD4 axis inhibitor SRX3262, which simultaneously blocks three interrelat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Dhananjaya, Vann, Kendra R., Joshi, Shweta, Sahar, Namood E., Morales, Guillermo A., El-Gamal, Dalia, Kutateladze, Tatiana G., Durden, Donald L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445847/
https://www.ncbi.nlm.nih.gov/pubmed/34557659
http://dx.doi.org/10.1016/j.isci.2021.102931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445847/
https://www.ncbi.nlm.nih.gov/pubmed/34557659
http://dx.doi.org/10.1016/j.isci.2021.102931

Ejemplares similares